Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Mar 18, 2015 8:22pm

197 Views

Post# 23536487

RE:RE:RE:RE:RE:RVX Analyst Report, CDN$5.85 target http://www.resverlo

I would not be surprised if RVX was working hard on a NASDAQ registration.

It sounds (from the posts of others on this board) like the chances of that go up if we get to the $2 and stay there. Due to NASDAQ registration rules for new registrating companies.

With a report like this, I think $2 is getting more and more likely.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity